Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Evolocumab In Advanced Chronic Kidney Disease Trial
NCT04510844 · NYU Langone Health · PHASE4 · withdrawn · last registry update 2022-07-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “loss of funding” | – | Registry record, NYU Langone Health |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PCSK9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-06-05Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran + Matching Placebo for Inclisiran (NCT05888103)
- 2023-05-10Results posted on the registry: Novartis Pharmaceuticals, Inclisiran sodium + Placebo (NCT04666298)
- 2023-05-06Results posted on the registry: Sanofi, Alirocumab SAR236553 (REGN727) + Rosuvastatin (NCT03510884)
- 2023-05-03Results posted on the registry: Annapoorna Kini, Evolocumab Injections (NCT04710368)
- 2023-03-27Also stopped (terminated): Amgen, evolocumab + placebo (NCT03433755)
- 2023-03-24Results posted on the registry: Novartis Pharmaceuticals, Inclisiran + Evolocumab (NCT03060577)
- 2023-03-15Results posted on the registry: University of California, Los Angeles, Repatha (NCT04573777)
- 2023-03-15Also stopped (terminated): University of California, Los Angeles, Repatha (NCT04573777)
- 2023-03-10Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran + Ezetimibe (NCT05763875)
- 2023-03-08Results posted on the registry: Robert Rosenson, Placebo + Evolocumab (NCT03829046)
- 2023-02-28Results posted on the registry: Amgen, Evolocumab (NCT02867813)
- 2023-02-23Phase 3 first posted: The First Affiliated Hospital with Nanjing Medical University, Evolocumab + Atorvastatin (NCT05741086)
- 2023-02-22Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml (NCT05739383)
- 2023-02-10Results posted on the registry: Regeneron Pharmaceuticals, Evinacumab + Matching placebo (NCT03175367)
- 2023-01-19Results posted on the registry: Inova Health Care Services, Evolocumab + Placebo (NCT03258281)
- 2023-01-19Also stopped (terminated): Inova Health Care Services, Evolocumab + Placebo (NCT03258281)
- 2023-01-12Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran (NCT05682378)
- 2023-01-11Results posted on the registry: Amgen, Evolocumab (NCT03080935)
- 2022-11-10Results posted on the registry: Novartis Pharmaceuticals, Inclisiran Sodium for injection + Placebo (NCT03851705)
- 2022-08-19Also stopped (terminated): Gloria Vega, Alirocumab + Alirocumab placebo (NCT03004001)
- 2022-05-04Phase 3 first posted: Novartis Pharmaceuticals, Inclisiran sodium 300 mg + Placebo (NCT05360446)
- 2022-04-13Phase 3 first posted: Shanghai Junshi Bioscience Co., Ltd., Ongericimab + Placebo (NCT05325203)
- 2022-02-17Results posted on the registry: University of Florida, Evolocumab (NCT03096288)
- 2022-02-10Phase 3 first posted: LIB Therapeutics LLC, lerodalcibep (NCT05234775)
- 2022-02-10Results posted on the registry: LIB Therapeutics LLC, LIB003 (NCT03847974)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision